[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-340944-105":59,"doc-detail-340944-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","parp-inhibitor-era-in-ovarian-cancer-treatment-a-systematic-review-and-metaanalysis-of-randomized-controlled-trials","PARP inhibitor era in ovarian cancer treatment - a systematic review and metaanalysis of randomized controlled trials","","Ovarian cancer remains a leading cause of cancer-related death in women, often diagnosed late and prone to relapse. This systematic review and meta-analysis assesses the efficacy and safety of PARP inhibitors in advanced disease within randomized controlled trials. Outcomes focus on progression-free survival, overall survival, and adverse events, using pooled hazard and risk ratios with random-effects modeling.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/parp-inhibitor-era-in-ovarian-cancer-treatment-a-systematic-review-and-metaanalysis-of-randomized-controlled-trials/340944/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/parp-inhibitor-era-in-ovarian-cancer-treatment-a-systematic-review-and-metaanalysis-of-randomized-controlled-trials/340944.png","ImageObject",300,407,{"name":92,"@type":93},"Anda","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the goal of this systematic review and meta-analysis?","Question",{"text":112,"@type":113},"To evaluate the efficacy and safety of PARP inhibitors for treating advanced ovarian cancer in randomized controlled trials.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which outcomes were analyzed as primary endpoints?",{"text":117,"@type":113},"Progression-free survival, overall survival, and adverse events.",{"name":119,"@type":110,"acceptedAnswer":120},"What overall benefit did PARP inhibitor maintenance show in recurrent ovarian cancer?",{"text":121,"@type":113},"PARPi maintenance therapy produced a significant progression-free survival benefit over placebo across multiple patient subgroups.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},340944,1790413996,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962075006959,"https://ap-avatar.wpscdn.com/avatar/e0002397efbe92a78e?_k=1776741047341049297","Baradács et al. Journal of Ovarian Research (2024) 17:53 Journal of Ovarian Research  \n[https://doi.org/10.1186/s13048-024-01362-y](https://doi.org/10.1186/s13048-024-01362-y)  \n REVIEW Open Access  \nPARP inhibitor era in ovarian cancer treatment: a systematic review and metaanalysis of randomized controlled trials  \nIstván Baradács 1,2, Brigitta Teutsch2,3, Alex Váradi3, Alexandra Bilá2,6, Ádám Vincze2,6, Péter Hegyi2,3,4,  \nTamás Fazekas2,5, Balázs Komoróczy1,2, Péter Nyirády2,5, Nándor Ács1,2, Ferenc Bánhidy1,2 and Balázs Lintner 1,2*  \nAbstract  \nBackground Ovarian cancer is the eighth leading cause of cancer-related death among women, characterized by late diagnosis and a high relapse rate. In randomized controlled trials, we aimed to evaluate the efficacy and safety of PARP inhibitors (PARPi) in treating advanced ovarian cancer.  \nMethods This review was registered on PROSPERO (CRD42021283150), included all phase II and phase III randomized controlled trials (RCTs) assessing the effect of PARPi on ovarian cancer until the 13th of April, 2022. The main outcomes were progression-free survival (PFS), overall survival (OS), and adverse events (AEs) . Pooled hazard ratios (HRs), and risk ratios (RRs) were calculated with 95% confidence intervals (95% CI) . The random-effects model was applied in all analyses.  \nResults In the meta-analysis, 16 eligible RCTs were included, with a total of 5,815 patients. In recurrent ovarian cancer, PARPi maintenance therapy showed a significant PFS benefit over placebo in the total population (HR 0 . 34, CI 0.29– 0.40), BRCA mutant (HR 0 . 24, CI 0.18–0. 31), germline BRCA mutant (HR 0 . 23, CI 0.18–0. 30), and BRCA wild-type cases (HR 0 . 50, CI 0.39–0. 65) . PARPi monotherapy also improved PFS (HR 0 . 62, CI 0.51–0. 76) compared with chemotherapy in BRCAm patients with recurrent ovarian cancer. The use of PARPi maintenance therapy resulted in an improvement in PFS over placebo in newly-diagnosed cancers in the overall population (HR 0 .46, CI 0.30–0. 71) and the BRCAm population (HR 0 . 36, CI 0.29–0.44) . Although the risk of severe AEs was increased by PARPi therapy compared to placebo in most settings investigated, these side effects were controllable with dose modification, and treatment discontinuation was required in the minority of cases.  \nConclusions PARPis are an effective therapeutic option for newly-diagnosed and recurrent ovarian cancer. Despite a minor increase in the frequency of serious adverse effects, they are generally well tolerated.  \nKeywords Olaparib, Niraparib, Rucaparib, HRD, Homologous recombination repair  \n*Correspondence: Balázs Lintner [lintnerster@gmail.com](lintnerster@gmail.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ()[. The Creative Commons Public Domain Dedication waiver (](http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ()[http://creativecom](http://creativecom)[mons.org/publicdomain/zero/1.0/](mons.org/publicdomain/","cbCaiufR26Qp0gSo","https://ap.wps.com/l/cbCaiufR26Qp0gSo","pdf",2460280,14,"English","# Abstract\n# Background\n# Methods\n# Results\n# Conclusions\n# Introduction","[{\"question\":\"What was the goal of this systematic review and meta-analysis?\",\"answer\":\"To evaluate the efficacy and safety of PARP inhibitors for treating advanced ovarian cancer in randomized controlled trials.\"},{\"question\":\"Which outcomes were analyzed as primary endpoints?\",\"answer\":\"Progression-free survival, overall survival, and adverse events.\"},{\"question\":\"What overall benefit did PARP inhibitor maintenance show in recurrent ovarian cancer?\",\"answer\":\"PARPi maintenance therapy produced a significant progression-free survival benefit over placebo across multiple patient subgroups.\"}]","PARP inhibitor era in ovarian cancer treatment - a systematic review and metaanalysis of randomized controlled trials | PDF",1790039647,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7834f12896f5b347d358a61d7906b3bc.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bc95a3082563a2cf78dead68b1e69155.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fc3070a076533c60b492a5defa32d3ea.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/64b5a658455f18e45dc15944498ab6f7.webp",980,1301]